SK609 (ES609) is a Dopamine D3 receptor (D3R) selective agonist with a bias towards the G-protein-dependent pathway rather than recruiting β-arrestin-2 and an EC50 value of 113.9 nM for activation of ERK1/2 phosphorylation. SK609 has been shown to reverse akinesia and reduce L-dopa-induced dyskinesia in a hemiparkinsonian rat model of Parkinson′s desease. It does not induce desensitization of D3R.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Synthetic dopaminergic agents have found utility in treating neurological and neuropsychiatric disorders since the beginning of 19th century. The discovery of Levodopa (l-dopa) to effectively treat motor symptoms of Parkinson's disease (PD) revolutionized the therapy and remains a gold standard
ACS chemical neuroscience, 8(3), 486-500 (2016-11-02)
Dopamine receptors play an integral role in controlling brain physiology. Importantly, subtype selective agonists and antagonists of dopamine receptors with biased signaling properties have been successful in treating psychiatric disorders with a low incidence of side effects. To this end
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
